Financial News
Crispr Therapeutics Ag (NQ: CRSP )
120.88
USD
+6.49
(+5.67%)
Official Closing Price
Updated: 5:55 PM EDT, Apr 13, 2021
Add to My Watchlist
Stories about Crispr Therapeutics Ag
40 Biggest Movers From Yesterday
January 23, 2018
From Benzinga
Mixed close as investors weigh solar import tariff
January 23, 2018
Tags
Market News
Chinese scientists use CRISPR technology
January 23, 2018
2 Gene Editing Stocks SunTrust Recommends
January 23, 2018
From Benzinga
Here's What's Driving Crispr Therapeutics AG Higher Today
January 23, 2018
From Motley Fool
33 Stocks Moving In Tuesday's Mid-Day Session
January 23, 2018
From Benzinga
8 Biggest Price Target Changes For Tuesday
January 23, 2018
From Benzinga
Benzinga's Top Upgrades, Downgrades For January 23, 2018
January 23, 2018
From Benzinga
28 Stocks Moving In Tuesday's Pre-Market Session
January 23, 2018
From Benzinga
CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again
January 15, 2018
From Motley Fool
10 Things to Expect From Vertex Pharmaceuticals in 2018
January 08, 2018
From Motley Fool
22 Stocks Moving In Monday's Pre-Market Session
January 08, 2018
From Benzinga
Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless
January 08, 2018
From Motley Fool
Markets surge even as job growth slows
January 05, 2018
Tags
Market News
BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
January 04, 2018
Tags
companyNews
Here's Why Intellia Therapeutics Inc. Fell 14.7% in December
January 04, 2018
From Motley Fool
Here's What Pushed Crispr Therapeutics AG Up 23.6% in December
January 04, 2018
From Motley Fool
40 Biggest Movers From Yesterday
January 03, 2018
From Benzinga
From Benzinga
30 Stocks Moving In Wednesday's Mid-Day Session
January 03, 2018
From Benzinga
Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide
January 03, 2018
From Benzinga
Mid-Morning Market Update: Markets Open Higher; Commercial Metals Profit Beats Estimates
January 03, 2018
From Benzinga
25 Stocks Moving In Wednesday's Pre-Market Session
January 03, 2018
From Benzinga
Tags
companyNews
CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know
December 22, 2017
From Motley Fool
Q&A: Vertex Chief Talks About Company's 'Transformational Year'
December 22, 2017
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
